Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study
Camostat mesylate is expected to be promising as a treatment option for COVID-19, in addition to other indications for which it is currently used. Furthermore, in vitro experiments have confirmed the potential of camostat and its metabolites to be effective against COVID-19. Therefore, clinical tria...
Saved in:
Main Authors: | Gwanyoung Kim (Author), Hyun-ki Moon (Author), Taeheon Kim (Author), So-hye Yun (Author), Hwi-yeol Yun (Author), Jang Hee Hong (Author), Dae-Duk Kim (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power‐law based pharmacokinetic modeling
by: Taeheon Kim, et al.
Published: (2024) -
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
by: Junsaku Kitagawa, et al.
Published: (2021) -
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
by: M. Karolyi, et al.
Published: (2022) -
A compatibility evaluation between the physiologically based pharmacokinetic (PBPK) model and the compartmental PK model using the lumping method with real cases
by: Hyo-jeong Ryu, et al.
Published: (2022) -
Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
by: Akmaral Assylbekova, et al.
Published: (2022)